Focus: Bavarian Nordic is a mid-cap vaccine biotech headquartered in Denmark with 1,001-5,000 employees, focused on infectious disease vaccines and immunotherapies across infectious and oncology indications.
Profile data last refreshed 10h ago · AI intelligence enriched 2w ago
Cooling — net -9 jobs in 30d
18 added, 27 removed. Slower than typical.
Bavarian Nordic is a solid mid-stage vaccine specialist best suited for professionals seeking manufacturing scale-up, regulatory, or early-stage commercialization experience in infectious disease rather than pure discovery roles.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Multiple Phase 2 programs indicate active development and clinical advancement in biodefense/public health preparedness.
Help build intelligence for Bavarian Nordic
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bavarian Nordic's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Phase 3 status positions this as a near-term commercialization candidate in response to 2022+ mpox outbreak demand.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles